[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100301846":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":21,"locations":30,"responsibleParty":68,"collaborators":10,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":73,"sex":78,"minAge":79,"maxAge":10,"enrollmentInfo":80,"targetDuration":10,"studyType":83,"phases":10,"briefSummary":84,"conditions":85,"keywords":91,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"Medical University of Silesia","OTHER",[8,12,15,18],{"label":9,"type":10,"description":11,"interventionNames":10},"Stable coronary artery disease",null,"Patients with stable effort angina wil be enrolled. Based on coronary angiography, heart team will decide on medical, percutaneous angioplasty, or bypass grafting.",{"label":13,"type":10,"description":14,"interventionNames":10},"Unstable coronary artery disease","Patients with unstable angina wil be enrolled. Based on coronary angiography, heart team will decide on medical, percutaneous angioplasty, or bypass grafting.",{"label":16,"type":10,"description":17,"interventionNames":10},"Non-ST elevation myocardial infarction","Patients with non-ST elevation myocardial infarction wil be enrolled. Based on coronary angiography, heart team will decide on medical, percutaneous angioplasty, or bypass grafting.",{"label":19,"type":10,"description":20,"interventionNames":10},"ST-elevation myocardial infarction","Patients with ST elevation myocardial infarction wil be enrolled. In majority of patients primary percutaneous coronary intervention will be performed. Based on coronary angiography, heart team will decide on further medical treatment, percutaneous angioplasty, or bypass grafting.",[22,27],{"name":23,"role":24,"phone":25,"phoneExt":10,"email":26},"Andrzej R Tomasik, M.D. Ph.D., FESC","CONTACT","0048323732372","tomasik@poczta.onet.pl",{"name":28,"role":24,"phone":25,"phoneExt":10,"email":29},"Ewa Nowalany-Kozielska, Prof.","kl2karz@sum.edu.pl",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"II Dept. of Cardiology in Zabrze Medical University of Silesia","RECRUITING","Zabrze","Upper Silesia","41-800","Poland","PL",{"type":40,"coordinates":41},"Point",[42,43],18.78576,50.32492,{"lat":43,"lon":42},[46,48,50,53,56,58,60,62,64,66],{"name":47,"role":24,"phone":25,"phoneExt":10,"email":29},"Beata Matyjaszczuk",{"name":49,"role":24,"phone":25,"phoneExt":10,"email":29},"Lidia Stankiewicz",{"name":51,"role":52,"phone":10,"phoneExt":10,"email":10},"Andrzej R Tomasik, MD PhD FESC","PRINCIPAL_INVESTIGATOR",{"name":54,"role":55,"phone":10,"phoneExt":10,"email":10},"Ewa Wołoszyn-Horak, MD","SUB_INVESTIGATOR",{"name":57,"role":55,"phone":10,"phoneExt":10,"email":10},"Robert Salamon, MD",{"name":59,"role":55,"phone":10,"phoneExt":10,"email":10},"Jakub Standera",{"name":61,"role":55,"phone":10,"phoneExt":10,"email":10},"Łukasz Bieda",{"name":63,"role":55,"phone":10,"phoneExt":10,"email":10},"Katarzyna Chojnacka",{"name":65,"role":55,"phone":10,"phoneExt":10,"email":10},"Aleksandra Brzosko",{"name":67,"role":55,"phone":10,"phoneExt":10,"email":10},"Ewa Nowalany-Kozielska, Prof",{"type":52,"investigatorFullName":69,"investigatorTitle":70,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Andrzej Tomasik MD PhD FESC","Assistant professor","100301846","frailty-syndrome-in-daily-practice-of-interventional-cardiology-ward-100301846",false,"NCT03209414","Frailty Syndrome in Daily Practice of Interventional Cardiology Ward","FRAPICA","Inclusion Criteria:\n\n* aged ≥ 65\n* symptomatic coronary artery disease A) stable B) unstable C) NSTEMI D) STEMI\n* written, informed consent\n\nExclusion Criteria:\n\n* lack of consent","ALL","65 Years",{"count":81,"type":82},1000,"ESTIMATED","OBSERVATIONAL","The impact of frailty on immediate and long term outcomes of invasive treatment of coronary artery disease is not fully characterized. The assessment of frailty may help physicians in the selection of best treatment option and in the timing and modality of the follow-up. The FRAilty syndrome in daily Practice of Interventional CArdiology ward (FRAPICA) study is designed with the aim to validate the use of the Fried frailty scale and instrumental activities of daily living scale (IADL) as prognostic tools in patients admitted to hospital for symptomatic coronary artery disease, either stable, unstable, or acute coronary syndrome (ACS).\n\nThe FRAPICA study is a single center prospective study enrolling patients aged ≥65 years. The aims are (1) to describe Fried frailty scale and IADL scale distribution before hospital discharge and (2) to investigate the prognostic role of Fried frailty and IADL scores. The outcomes are: (1) results of invasive treatment, (2) its complications (periinterventional MI, contrast-induced nephropathy, blood loss), (3) three-year all-cause mortality, cardiovascular mortality, stroke, myocardial infarction, reintervention, heart failure, hospital readmission for any cause, and a composite of the above mentioned. Ancillary analyses will be focused on different clinical presentations, different tools to assess frailty and risk stratification.\n\nThe FRAPICA program will fill critical gaps in the understanding of the relation between frailty, cardiovascular disease, interventional procedures and outcome. It will enable more personalized risk assessment and identification of new targets for interventions.",[86,87,88,89,90],"Frail Elderly Syndrome","Coronary Heart Disease","Acute Coronary Syndrome","Coronary Artery Bypass Grafting","Percutaneous Transluminal Coronary Angioplasty",[92,93,94,95,96,97,98,99],"Frailty syndrome","Coronary heart disease","Coronary revascularization","Major adverse cardiovascular events","Arterial stiffness","Applanation tonometry","Lean body mass","ST2 biomarker","2023-04-10",{"date":102,"type":103},"2023-04-12","ACTUAL",{"date":105,"type":103},"2017-05-17",{"date":107,"type":82},"2027-12-31",{"name":5,"class":6},1]